221 related articles for article (PubMed ID: 25270772)
21. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
Panieri E; Saso L
Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
[No Abstract] [Full Text] [Related]
22. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
23. Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila.
Sykiotis GP; Bohmann D
Dev Cell; 2008 Jan; 14(1):76-85. PubMed ID: 18194654
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
25. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
[TBL] [Abstract][Full Text] [Related]
26. Molecular Mechanisms Underlying Hepatocellular Carcinoma Induction by Aberrant NRF2 Activation-Mediated Transcription Networks: Interaction of NRF2-KEAP1 Controls the Fate of Hepatocarcinogenesis.
Haque E; Karim MR; Salam Teeli A; Śmiech M; Leszczynski P; Winiarczyk D; Parvanov ED; Atanasov AG; Taniguchi H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751080
[TBL] [Abstract][Full Text] [Related]
27. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.
Telkoparan-Akillilar P; Panieri E; Cevik D; Suzen S; Saso L
Molecules; 2021 Mar; 26(5):. PubMed ID: 33808001
[TBL] [Abstract][Full Text] [Related]
29. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
Gorrini C; Gang BP; Bassi C; Wakeham A; Baniasadi SP; Hao Z; Li WY; Cescon DW; Li YT; Molyneux S; Penrod N; Lupien M; Schmidt EE; Stambolic V; Gauthier ML; Mak TW
Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4472-7. PubMed ID: 24567396
[TBL] [Abstract][Full Text] [Related]
30. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
Ichikawa T; Li J; Meyer CJ; Janicki JS; Hannink M; Cui T
PLoS One; 2009 Dec; 4(12):e8391. PubMed ID: 20027226
[TBL] [Abstract][Full Text] [Related]
31. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
32. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.
Zhang DD; Lo SC; Cross JV; Templeton DJ; Hannink M
Mol Cell Biol; 2004 Dec; 24(24):10941-53. PubMed ID: 15572695
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic studies of the Nrf2-Keap1 signaling pathway.
Zhang DD
Drug Metab Rev; 2006; 38(4):769-89. PubMed ID: 17145701
[TBL] [Abstract][Full Text] [Related]
34. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract][Full Text] [Related]
35. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract][Full Text] [Related]
36. Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism.
Smolková K; Mikó E; Kovács T; Leguina-Ruzzi A; Sipos A; Bai P
Antioxid Redox Signal; 2020 Nov; 33(13):966-997. PubMed ID: 31989830
[No Abstract] [Full Text] [Related]
37. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1.
Malhotra D; Thimmulappa R; Navas-Acien A; Sandford A; Elliott M; Singh A; Chen L; Zhuang X; Hogg J; Pare P; Tuder RM; Biswal S
Am J Respir Crit Care Med; 2008 Sep; 178(6):592-604. PubMed ID: 18556627
[TBL] [Abstract][Full Text] [Related]
38. Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment.
Moon EJ; Giaccia A
Free Radic Biol Med; 2015 Feb; 79():292-9. PubMed ID: 25458917
[TBL] [Abstract][Full Text] [Related]
39. Potential Applications of NRF2 Inhibitors in Cancer Therapy.
Panieri E; Saso L
Oxid Med Cell Longev; 2019; 2019():8592348. PubMed ID: 31097977
[TBL] [Abstract][Full Text] [Related]
40. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
